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Abstract
In 1992, the American Cancer Society (ACS) recommended annual 
screening for prostate cancer for men 50 and older using PSA. In this 
article, I introduce a method to use race and age-specific PSA accuracy 
data to evaluate differences in the valuation of outcomes by race and 
age that were expressed by the ACS guidelines. Using this new method, 
it can be concluded that the guidelines implied a 4-fold greater valua-
tion was assigned to screening young white males with prostate cancer 
than the value that was assigned to young black males with cancer. 
Future implementation of guidelines for screening and testing should 
recognize and rectify any social inequities that are expressed via their 
implementation. 
Key Words:  diagnostic technology, health policy, ROC Curve, PSA,  
prostate cancer
Introduction
The aphorism ‘actions speak louder than words’ is no less true in 
Medicine than it is elsewhere. When actions are the result of decision-
making, they then express something about the decision-maker. The 
action of a 17-year-old driver careening 100 mph on a highway expresses 
a relative valuation on life versus death and of the relative likelihood of 
these two outcomes in the mind of the decision-maker. In equal parts, 
the 1992 recommendations of the American Cancer Society1 for prostate 
cancer screening beginning at age 50 using Digital Rectal Examination 
(DRE) and  PSA with threshold 4.0 ng/ml expresses something about the 
relative valuation and likelihood of the outcomes of screening diseased 
and non-diseased individuals held by implementers of those guidelines.
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A rational decision maker uses diagnostic technology in such a way 
so as to maximize the benefit from the technology while minimizing the 
cost. Whether or not the ways diagnostic technologies are actually used 
in medicine comes about from rational decision processes, the perspec-
tive of the rational decision-maker can always be relied upon to provide 
a universally acceptable referent, much as is done in Economics. This 
reference perspective can, among other things, provide a consistent 
framework for interpreting observed behavior.
In this paper, I adopt the perspective of the rational decision-maker 
to derive a measure of the relative valuation of health outcomes that is 
expressed by the observed use of a diagnostic technology in a clinical 
population. The method inverts a fundamental result from Clinical Deci-
sion Analysis that is used to optimize the use of a diagnostic technology. 
As an example, I apply this method to then use race and age specific data 
published about the accuracy of PSA testing to determine the relative 
valuations that were expressed by 1992 ACS guidelines for the screening 
of prostate cancer using PSA.1  The 1992 guidelines were selected solely 
to provide an example of the method and the insights the method can 
provide. My paper does not attempt to evaluate guidelines currently 
used in practice.
Methods
The choices involved in the application of a diagnostic technology 
in a defined clinical population are expressed in something called the 
“Receiver Operating Characteristic (ROC) Curve.”2  The ROC Curve 
is a graphical display of all of the Sensitivity-False Positive Probability 
combinations that are possible by the selection of various thresholds. 
For example, application of the PSA test requires selection of a threshold 
value to define a positive test result. Recommendations made by the ACS 
in 1992 were for 4.0 ng/ml1 and this cutoff provides an estimated Sensi-
tivity and False Positive Probability for white males 70-79 years old of 
98.6% and 26.9%, respectively3. Each such threshold selection provides a 
different True Positive-False Positive probability combination. Selection 
of other thresholds yields other combinations and the entire set of such 
combinations can be graphically displayed in the ROC Curve. Figure 1, 
for example, plots the ROC curve for PSA when applied to white males 
70-79 years old. The curve is estimated from data published by Morgan.3
To implement a diagnostic technology, a rational decision-maker de-
termines the threshold value that maximizes benefit and minimizes cost. 
Fortunately, the solution, well known in the Clinical Decision Analysis 
literature, is straightforward.4 The rational decision maker selects the
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FIGURE 1.  ROC Curve of PSA for white men 70-79. Each point on the curve represents the 
sensitivity-false positive probability arising from the selection of a threshold for PSA  
testing.
threshold at which the slope of the ROC Curve equals the product of the 
relative probability of non-disease times the relative value of applying 
the test in the non-diseased versus the diseased populations.4,5  In short-
hand, this can be expressed as:
Choose the threshold at which,
ROC Slope = (Relative probability of Non-disease)(Relative Value of Non-disease)
To anchor these terms, it helps to note that the “Relative Probability of 
Non-disease” is the odds of not having disease. That is, if “p” is the prevalence 
of disease in the population, then (Relative Probability of Non-disease) = (1-
p)/p.  Although it is not necessary to restrict the measurement of outcomes to 
monetary units, it is helpful to think about the term “Relative Value of Non-
disease” in terms of costs. Let “cTP”, “cFN”, “cFP” and “cTN” represent the “costs” 
related to True Positives, False Negatives, False Positive and True Negatives 
(negative cost implies benefit). Then, Relative Value of Non-disease = (cTN-
cFP)/(cTP-cFN)4.
The previous relationship can be inverted. If we observe the use of a 
diagnostic technology, and if we have knowledge of the odds of non-dis-
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ease and of the ROC Curve of the technology, we can then infer the rela-
tive valuation of outcomes by the rational decision-maker: The Relative 
Value (non-diseased to diseased) that is expressed by the rational use of a 
diagnostic technology equals the “Relative Probability of Disease” times 
the slope of the ROC Curve at the point observed to be used in practice. 
Symbolically,
Expressed Relative Value of Non-diseased =  
 (Relative probability of Disease)(ROC Slope) 
          where “Relative Probability of Disease” is the odds of disease= p/(1-p).
It is important to point out that computation of this measure requires 
the computation of the slope of the ROC Curve at the operating point 
used in practice. Hence, the analyst must have first the ROC Curve of 
the technology. This can be accomplished by appropriately designed and 
conducted technology assessment studies. Hopefully, such studies can be 
sourced from the literature.
Results
Table 1 presents the results of the application of this new method.  In 
1992, the American Cancer Society1 recommended annual screening for 
prostate cancer for men 50 and older using both DRE and PSA. Here, I 
consider only the implications of the ACS recommendation of PSA-based 
screening for prostate cancer using the threshold of 4.0 ng/ml. Morgan3 
estimated ROC Curves for PSA testing in the detection of prostate cancer 
for various age groups of white and black men. I then used this data to 
estimate the slope of each ROC Curve at the ACS-recommended thresh-
old for each age-race specific ROC Curve after assuming that PSA levels 
are normally distributed. Estimates of age and race specific prevalence 
were obtained from SEER tables6 and were then used to estimate the 
odds of disease. The relative value of outcomes (no prostate cancer vs. 
prostate cancer) expressed by the ACS guidelines was then computed us-
ing the previous formula. This number is reported as “Relative Value of 
Non-diseased” in the table. To facilitate interpretation, the reciprocal also 
appears in the table and is denoted by “Relative Value of Diseased.” This 
value can be interpreted as the value of outcomes in applying the screen-
ing test to the population with prostate cancer relative to the value when 
screening the population without prostate cancer.
Focusing on “Relative Value of Diseased,” we can observe that 
screening young men (40-49) for prostate cancer had greater expressed 
relative value than screening older men in both racial groups. However, 
some racial disparities in this pattern do occur. For example, the relative 
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TABLE 1.  Relative values in prostate cancer screening expressed by 1992 ACS guidelines.
Whites Relative Value
Age Slopea Prevalenceb Non-Diseasedc Diseasedd
40-49 4.341 9.1 0.000395 2531.645570
50-59 5.453 146.75 0.008016 124.750499
60-69 3.211 713.8 0.023084 43.320049
70-79 1.833 1353.45 0.025149 39.763012
Blacks Relative Value
Age Slopea Prevalenceb Non-Diseasedc Diseasedd
40-49 7.654 15.7 0.001202 831.946755
50-59 0.898 273.45 0.002462 406.173842
60-69 0.431 1086.5 0.004734 211.237854
70-79 0.108 1868.1 0.002056 486.381323
a Based on cutoff of 4.0 ng/ml
b Per 100,000/year
c Value of outcomes from screening men without cancer relative to the value from screening men with cancer
d Value of outcomes from screening men with cancer relative to the value from screening men without cancer
 
value of screening steadily declines with increasing age for white males. 
This is consistent with the opinion that the effectiveness of screening for 
and treatment of prostate cancer declines with advancing age. However, 
this pattern is not strictly followed for black males. The 1992 ACS guide-
lines suggested that the relative value of screening is less for black males 
in the age groups 50-59 and 60-69 than it is for males from the oldest age 
group (70-79). 
Another salient observation from the table is that the relative value 
of screening young white men is at least 20 times larger than the ex-
pressed value of screening white men from any other white age group. 
On the other hand, the relative values for black males are much more 
homogeneous. The relative value of screening a young black male is at 
most 4 times that of screening black males from another age group. 
Finally, we can observe that if the value of health outcomes in screen-
ing young healthy men were the same for both racial groups, then the 
guidelines express a four-fold greater valuation for screening young 
white males (40-49) with prostate cancer than the value assigned to 
young black males.
Discussion
The value of health outcomes that is expressed by the use of a diag-
nostic technology is the relative value implied had a rational decision 
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maker aware of the disease prevalence and operating characteristics of 
the technology in the clinical population of interest implemented the 
technology. What better perspective is there to understand the implica-
tions of the observed use of diagnostic technology than from the univer-
sally-accepted perspective of rationality? Is there a decision-maker not 
willing to affirm that it is best, when possible, to maximize benefit and 
minimize cost?
Had the 1992 ACS recommendations been made from a rational 
perspective, we would conclude that the maker of these recommenda-
tions valued outcomes quite differently for white and black men. The 
monotonicity of declining values for white men seems to be logical since 
one might anticipate the benefits from screening to decline with age. This 
coherent pattern does not hold for black males. Is this anomaly accept-
able to modern thought in Medicine?  
The ACS recommendations also express an astronomically high 
value for screening young white men compared to young black men. 
This discrepancy, although probably unintended, nonetheless expresses 
a substantial inequity. Is this desirable?
The utility of the measure introduced in this paper is that it provides 
a universally acceptable metric with which individuals having widely 
varying perspectives can commonly view the implications of the use of 
diagnostic technology. It is not important whether rational decision mak-
ing processes were actually followed when the diagnostic technology 
was implemented. The goal is simply to provide a universal frame-of-ref-
erence for measurement, communication and discovery.
Limitations
A limitation of this paper is that it provides only the essential back-
ground required to understand and apply this new measure. The reader 
considering use of this measure should consult the burgeoning literature 
that has arisen over the past twenty years around ROC Curves in partic-
ular and the evaluation of diagnostic technologies in general.  Recently, 
two comprehensive overviews have appeared in book form.7,8
I have focused this analysis on the 1992 ACS guidelines simply in 
the hope that distance in time will promote objective discussion of this 
new methodology. Another limitation of the current paper is the focus 
on PSA screening and not PSA combined with DRE as was considered by 
the guidelines. However, this limitation points out the need for data to be 
collected that provides the ROC curve of PSA combined with DRE strati-
fied by race and age. Analysis with contemporary data and contempo-
rary guidelines should of course be conducted. If such findings replicate 
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the findings made in this paper, then we might seek to fashion health 
policy for the use of PSA in screening that is specifically directed at less-
ening expressed racial inequities. How would this be accomplished? The 
rationalist approach tells us to first establish the value of health outcomes 
for each age group and consider these as equal for both racial groups. 
Then, using updated ROC Curves, select PSA testing thresholds that are 
optimal for each age-race group.
In general, the methodology introduced in this paper introduces 
a vantage point with which the implications of the use of diagnostic 
technology can be quantitatively assessed. Hopefully, awareness of the 
implications of our actions in screening and diagnosis gained through 
the use of similar analyses will point the direction to improved health 
care by lessening unintended, yet nonetheless expressed, inequalities.
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